Europos Sąjunga - anglų - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain in adults.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetin delta - kidney failure, chronic; anemia - antianemic preparations - dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult patients. it may be used in patients on dialysis and in patients not on dialysis.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer limited - insulin human - diabetes mellitus - drugs used in diabetes - exubera is indicated for the treatment of adult patients with type 2 diabetes mellitus notadequately controlled with oral antidiabetic agents and requiring insulin therapy.exubera is also indicated for the treatment of adult patients with type 1 diabetes mellitus, inaddition to long or intermediate acting subcutaneous insulin, for whom the potential benefits ofadding inhaled insulin outweigh the potential safety concerns (see section 4.4).

Europos Sąjunga - anglų - EMA (European Medicines Agency)

unigene uk ltd. - recombinant salmon calcitonin - hypercalcemia; osteitis deformans; bone resorption - calcium homeostasis - calcitonin is indicated for:prevention of acute bone loss due to sudden immobilisation such as in patients with recentosteoporotic fracturespaget's diseasehypercalcaemia of malignancy

Europos Sąjunga - anglų - EMA (European Medicines Agency)

ecuphar - meloxicam - anti inflammatory and antirheumatic products - dogs; cats - oral suspension:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.solution for injection:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.cats:reduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer limited - e2 glycoprotein of classical swine fever virus - immunologicals for suidae - pigs - active immunisation of pigs, over the age of 2 weeks, against classical swine fever (csf), to preventmortality, reduce clinical signs of the disease and the excretion of field virus.the onset of protection is 2 weeks.the duration of protection is 6 months.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

sanofi pasteur s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

merial - inactivated ibr virus - immunologicals for bovidae - cattle - active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion., the onset of immunity is 14 days and the duration of immunity is 6 months.,

Europos Sąjunga - anglų - EMA (European Medicines Agency)

merial - bluetongue-virus serotype-1 antigen - immunologicals - sheep; cattle - active immunisation of sheep and cattle to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotype 1.onset of immunity has been demonstrated three weeks after the primary vaccination course. the duration of immunity for cattle and sheep is one year after the primary vaccination course.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

merial - bluetongue virus serotype 8 antigen - immunologicals for ovidae, immunologicals for bovidae - sheep; cattle - active immunisation of sheep and cattle to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotype 8.*(below the level of detection by the validated rt-pcr method at 3.14log10 rna copies/ml, indicating no infectious virus transmission).onset of immunity has been demonstrated 3 weeks after the primary vaccination course.the duration of immunity for cattle and sheep is 1 year after the primary vaccination course.the duration of immunity is not yet fully established in cattle or sheep, although interim results of ongoing studies demonstrate that the duration is at least 6 months after the primary vaccination course in sheep.